## ILMN: Illumina, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.62 indicates fundamental undervaluation. Quality metrics strong (ROE 31%). Consistent execution (3/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($126.51)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Illumina (NASDAQ: ILMN) invests in MyOme to launch AI-driven WGS trial in 2026**
- Source: Stock Titan | 20251211T141017 | Bullish | Relevance: 100%
- Illumina announced a strategic investment and collaboration with MyOme to support the MyOme Proactive Health (MPH) Trial, scheduled to begin enrollment in 2026. This trial will combine whole-genome sequencing (WGS) with MyOme's AI-integrated risk models (IRMs) for early disease detection, aiming for over $200 billion in annual U.S. healthcare savings. The initiative reflects Illumina's focus on preventive genomics and population health, with the investment also supported by Natera, Sequoia Capital, and The Duquesne Family Office.

**2. Nikko Asset Management Americas Inc. Increases Stake in Illumina, Inc. $ILMN**
- Source: MarketBeat | 20251214T110910 | Somewhat-Bullish | Relevance: 100%
- Nikko Asset Management Americas Inc. significantly increased its stake in Illumina, Inc. ($ILMN) by 28.8% in Q2, bringing its total holdings to 867,981 shares valued at approximately $82.8 million. Other institutional investors also raised their positions, leading to an overall institutional ownership of 89.42%. Despite a "Hold" consensus rating from Wall Street and an average price target of $115, Illumina exceeded its latest quarterly EPS and revenue estimates and provided positive FY2025 guidance.

**3. Ieq Capital LLC Buys 176,611 Shares of Illumina, Inc. $ILMN**
- Source: MarketBeat | 20251213T070910 | Somewhat-Bullish | Relevance: 100%
- Ieq Capital LLC significantly increased its stake in Illumina, Inc. (NASDAQ:ILMN) by 256.7%, adding 176,611 shares in the second quarter, bringing its total holdings to 245,409 shares valued at $23.41 million. Other institutional investors also raised their positions, contributing to an overall institutional ownership of 89.42%. Analysts maintain a consensus "Hold" rating with a $115 price target, while Illumina recently surpassed EPS estimates and provided positive FY2025 guidance.

**4. Using genomic testing to deliver hope to families**
- Source: Illumina | 20251212T200916 | Bullish | Relevance: 100%
- Dr. Yaron Goikhman, an obstetrician-gynecologist, experienced the challenges of IVF firsthand when initial PGT-A results for his embryos seemed to be inaccurate. This personal experience motivated him to expand access to safe and modern genetic tools in Central Asia and beyond, collaborating with experts to improve reproductive genetics services. Through the use of Illumina sequencers for high-throughput PGT and whole-exome sequencing, his team is helping families achieve healthy pregnancies, including a mother who conceived a healthy child after previous losses to spinal muscular atrophy.

**5. Ilex Capital Partners UK LLP Raises Stock Position in Illumina, Inc. $ILMN**
- Source: MarketBeat | 20251212T120916 | Somewhat-Bullish | Relevance: 100%
- Ilex Capital Partners UK LLP significantly increased its holdings in Illumina, Inc. (NASDAQ:ILMN) by 737.1% during Q2, now owning 154,119 shares valued at $14.7 million. Insider Scott Gottlieb also bought 500 shares, increasing his stake. Despite a "Hold" consensus rating and a $115 price target, Illumina's stock trades near $136, and the company exceeded Q3 EPS expectations and provided strong FY2025 guidance.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.09M) |
| Sells | 8 ($80.27M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 53.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Capital World Invest: 13.1% (+20.0%)
- Blackrock Inc.: 12.2% (-3.5%)
- Vanguard Group Inc: 9.6% (-3.5%)
- State Street Corpora: 3.9% (+6.8%)
- Sessa Capital IM, L.: 3.1% (-0.8%)

### Key Risks

1. Heavy insider selling: $80M sold (8 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +5.6% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.62 indicates undervaluation relative to growth. Forward P/E 27.0x stretched relative to 6% growth. Quality metrics strong (ROE 31%, margin 16%). Insider selling cluster ($80.3M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $20.7B |
| Beta | 1.44 |
| 52W Range | $68.70 - $153.06 |
| Short Interest | 7.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.62 |
| Forward P/E | 27.0 |
| Current P/E | 28.6 |
| YoY Growth | 6.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -0.1% to 5.4% (+5.6% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 77th percentile. MRS_5 at 2.7% confirms short-term momentum alignment. AM_20 at 5.8% shows strong absolute momentum above own 20MA. Outperforming sector by 5.7pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: -SUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 5.44% (CS: 78) | Strong |
| RSI_14 | 68.4 | Neutral |
| MACD Histogram | 0.05 | Bullish |
| vs SMA20 | 1.058x | Above |
| vs SMA50 | 1.181x | Above |
| vs SMA200 | 1.408x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $134.87
- **Stop Loss:** $126.51 (6.2% risk)
- **Target:** $151.59 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 119
- **Position Value:** $16,049.53
- **Portfolio %:** 16.05%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-05 (Est: $1.23)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.17 | $1.34 | +14.7% |
| 2025Q2 | $1.01 | $1.19 | +17.7% |
| 2025Q1 | $0.94 | $0.97 | +3.3% |
| 2024Q4 | $0.92 | $0.86 | -6.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*